Bouchra Tawk1, Christian Schwager1, Oliver Deffaa1, Gerhard Dyckhoff2, Rolf Warta3, Annett Linge4, Mechthild Krause4, Wilko Weichert5, Michael Baumann4, Christel Herold-Mende2, Jürgen Debus1, Amir Abdollahi6. 1. German Cancer Consortium (DKTK), Heidelberg, Germany; Molecular & Translational Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), University of Heidelberg Medical School and National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Germany. 2. Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Germany. 3. Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, Germany. 4. German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology, Germany. 5. German Cancer Consortium (DKTK), Heidelberg, Germany. 6. German Cancer Consortium (DKTK), Heidelberg, Germany; Molecular & Translational Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), University of Heidelberg Medical School and National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Germany. Electronic address: a.amir@dkfz.de.
Abstract
BACKGROUND AND PURPOSE: Hypoxia renders tumors resistant to radiotherapy. However, the paucity of sensitive and reliable methods for detection of tumor hypoxia limits the translation of novel therapy strategies targeting this well-known resistance factor. We sought to investigate the ability of three previously discovered transcriptomics based hypoxia signatures to identify hypoxic tumors and consequently discriminate between patients with poor- vs. good prognosis. MATERIAL AND METHODS: Three different hypoxia gene signatures developed by Toustrup et al., Eustace et al. and Lendahl et al. were evaluated in an independent cohort consisting of 302 patients with head and neck squamous cell carcinoma (HNSCC). Clinical data as well as genome-wide RNA-sequencing based gene expression data were retrieved from The Cancer Genome Atlas (TCGA). Clustering and statistical analysis were performed using Statistical Utilities for Microarray and Omics data (SUMO) software package. RESULTS: The 15 gene hypoxia signature developed by Toustrup et al. as well as the 30 gene signature by Lendahl et al. successfully discriminated between HNSCC patients with poor vs. good prognosis. The 26 gene signature developed by Eustace et al. was prognostic in HNSCC patients treated with radiotherapy. The best prognostic value was achieved when a consensus cohort of patients was assigned, i.e., low- or high- degree of tumor hypoxia was found, by all three signatures. Interestingly, the number of signature genes could be successfully reduced to the only common gene across all three signatures, i.e., P4HA1, encoding prolyl-4-hydroxylase, alpha polypeptide I. CONCLUSIONS: This is the first independent proof for the feasibility of hypoxia gene expression signatures as a prognostic tool in HNSCC patients.
BACKGROUND AND PURPOSE:Hypoxia renders tumors resistant to radiotherapy. However, the paucity of sensitive and reliable methods for detection of tumor hypoxia limits the translation of novel therapy strategies targeting this well-known resistance factor. We sought to investigate the ability of three previously discovered transcriptomics based hypoxia signatures to identify hypoxic tumors and consequently discriminate between patients with poor- vs. good prognosis. MATERIAL AND METHODS: Three different hypoxia gene signatures developed by Toustrup et al., Eustace et al. and Lendahl et al. were evaluated in an independent cohort consisting of 302 patients with head and neck squamous cell carcinoma (HNSCC). Clinical data as well as genome-wide RNA-sequencing based gene expression data were retrieved from The Cancer Genome Atlas (TCGA). Clustering and statistical analysis were performed using Statistical Utilities for Microarray and Omics data (SUMO) software package. RESULTS: The 15 gene hypoxia signature developed by Toustrup et al. as well as the 30 gene signature by Lendahl et al. successfully discriminated between HNSCCpatients with poor vs. good prognosis. The 26 gene signature developed by Eustace et al. was prognostic in HNSCCpatients treated with radiotherapy. The best prognostic value was achieved when a consensus cohort of patients was assigned, i.e., low- or high- degree of tumor hypoxia was found, by all three signatures. Interestingly, the number of signature genes could be successfully reduced to the only common gene across all three signatures, i.e., P4HA1, encoding prolyl-4-hydroxylase, alpha polypeptide I. CONCLUSIONS: This is the first independent proof for the feasibility of hypoxia gene expression signatures as a prognostic tool in HNSCCpatients.
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Jimmy J Caudell; Javier F Torres-Roca; Robert J Gillies; Heiko Enderling; Sungjune Kim; Anupam Rishi; Eduardo G Moros; Louis B Harrison Journal: Lancet Oncol Date: 2017-04-26 Impact factor: 41.316
Authors: Tomasz Kolenda; Weronika Przybyła; Marta Kapałczyńska; Anna Teresiak; Maria Zajączkowska; Renata Bliźniak; Katarzyna M Lamperska Journal: Rep Pract Oncol Radiother Date: 2018-03-17
Authors: Carmen Klein; Ivana Dokic; Andrea Mairani; Stewart Mein; Stephan Brons; Peter Häring; Thomas Haberer; Oliver Jäkel; Astrid Zimmermann; Frank Zenke; Andree Blaukat; Jürgen Debus; Amir Abdollahi Journal: Radiat Oncol Date: 2017-12-29 Impact factor: 3.481
Authors: Ludmila Wintergerst; Martin Selmansberger; Cornelius Maihoefer; Lars Schüttrumpf; Axel Walch; Christina Wilke; Adriana Pitea; Christine Woischke; Philipp Baumeister; Thomas Kirchner; Claus Belka; Ute Ganswindt; Horst Zitzelsberger; Kristian Unger; Julia Hess Journal: Mol Oncol Date: 2018-10-26 Impact factor: 6.603
Authors: Claudius Melzig; Azadeh Fahim Golestaneh; Walter Mier; Christian Schwager; Samayita Das; Julian Schlegel; Felix Lasitschka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn; Amir Abdollahi Journal: Oncotarget Date: 2018-07-06